Genetical analysis of all Danish patients diagnosed with chronic granulomatous disease

M A Jakobsen1, T L Katzenstein, N H Valerius

  • 1Department of Clinical Immunology, Odense University Hospital, Odense, Denmark. marianne.jakobsen@ouh.regionsyddanmark.dk

Insights

Genetic characterization of 27 Danish patients with Chronic Granulomatous Disease (CGD) identified mutations in key NADPH oxidase components. This study advances understanding of CGD genetics and provides a foundation for improved diagnostics.

Area of Science:

  • Immunology
  • Genetics
  • Molecular Biology

Background:

  • Chronic Granulomatous Disease (CGD) is a rare inherited primary immunodeficiency.
  • CGD results from defects in the NADPH oxidase enzyme complex, impairing phagocyte killing of microbes.
  • Mutations in CYBB, CYBA, NCF1, NCF2, and NCF4 genes cause CGD.

Purpose of the Study:

  • To genetically characterize a cohort of Danish patients with CGD.
  • To identify the specific genetic mutations responsible for CGD in this patient group.
  • To contribute to the understanding of CGD genetic heterogeneity.

Main Methods:

  • Collection of samples from all Danish CGD patients diagnosed or followed over a 5-year period.
  • Genetic characterization of 27 patients to identify causative mutations.
  • Analysis of mutations in X-linked CYBB and autosomal CYBA, NCF1, NCF2, and NCF4 genes.

Main Results:

  • The cohort comprised 27 patients, including 10 males with X-linked CGD and one female with skewed X-inactivation.
  • Mutations were identified in CYBA (6 patients) and NCF1 (10 patients), including novel mutations.
  • Three novel mutations were detected: a CYBA exon 6 deletion, a CYBB exon 8-13 duplication, and an NCF1 intron 7 splice site mutation.

Conclusions:

  • Genetic analysis confirmed the underlying mutations in the studied Danish CGD cohort.
  • The identification of novel mutations expands the known mutation spectrum for CGD.
  • This genetic data is crucial for accurate diagnosis, genetic counseling, and potential therapeutic strategies for CGD.